Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

or parkinsonism. Both of these scales documented minimal symptoms at baseline and there was no worsening during the six weeks of treatment. Clinical hematology, chemistry and ECG monitoring indicated no emergent safety signals.

There were no drug-drug interactions identified in subjects who were utilizing a range of psychotropic and other concomitant medications.

Next Steps for NBI-98854Data from the Kinect 2 study will be integrated with the Kinect study data to inform the ultimate design of the next study, Kinect 3. The Company will work with its consultants and scientific advisors to expand and refine the pharmacokinetic/pharmacodynamic models as well as to complete the remaining safety and efficacy analyses from both Kinect and Kinect 2. These data will form the basis for an End of Phase II briefing package along with the proposed Phase III protocol.

Kinect 2 Study DesignThe Kinect 2 Study was a randomized, parallel, double-blind, placebo-controlled, dose titration Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with an underlying mood disorder (e.g., bipolar disorder), schizophrenia or schizoaffective disorder, or a gastrointestinal disorder with exposure to metoclopramide. This 100 subject study assessed once-daily NBI-98854 over a six-week placebo-controlled dosing period. Half of the randomized subjects received placebo and half received NBI-98854. The NBI-98854 dosing regimen began with a once-daily dose of 25 mg for the initial two weeks. At the completion of the initial two weeks of dosing, based on certain efficacy and safety criteria, patients were titrated to a once-daily 50 mg dose, or continued on the once-daily 25 mg dose for the following two-week period. At the completion of the second two weeks of treatment another efficacy and safety assessment was performed and patients were eligible to be titrated to a once-daily 75 mg, 50 mg or 25 mg dose for the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fla. , March 3, 2015 ... pleased to announce the hiring of Brian ... to lead business development efforts and build relationships ... of experience in software development, sales, and sales ... enterprise software applications. iTraycer is a comprehensive inventory ...
(Date:3/3/2015)... -- Dr. Cummins is known for being one of ... In addition to performing cosmetic and hand surgery at ... Cummins now offers advanced laser tattoo removal treatments at ... performs all treatments himself using the industry-leading Astanza Duality ... order to help people take back control over the ...
(Date:3/3/2015)... --   Clinical trials at ... Publications in peer reviewed journals Gastrointestinal Endoscopy ... diagnostic value of confocal laser endomicroscopy in treatment of ... across Asia   ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today ...
Breaking Medicine Technology:Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Surgeon Owned And Operated Louisville Tattoo Removal Offers Astanza Duality Laser Treatments 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
... Disease Research Interchange, a Philadelphia-based national human tissue center ... awarded a $3.59 million subcontract from the National Institutes ... (Genotype-Tissue Expression). The funds for the 30-month project are ... NCI (the National Cancer Institute), NIMH (the National Institute ...
... FOUNTAIN HILLS, Ariz., Oct. 13 Sunridge International (OTC ... received an order for additional inventory from New Amsterdam ...  New Amsterdam personnel are currently on a two-week marketing ...  New Amsterdam,s personnel is accompanied by Leo D. Bores ...
Cached Medicine Technology:NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 2NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 3NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, 'The Directors Common Fund' to Provide Human Tissue for 'GTEx,' the New Genotype-Tissue Expression Project 4
(Date:3/3/2015)... The human augmentation market is mainly driven ... wearable augmentation sector is predicted to outpace the in-built ... years. , The eye-wear sector dominates the North ... of new products launches in the region. Furthermore, strong ... as well as the rising demand for advantageous products ...
(Date:3/3/2015)... While it is clear that the prospect of reduced ... are signing up to UBI policies, more mature audiences ... Due to current regulations, the application of UBI in ... full capability is starting to be realised in the ... services are at the top of the value-added services ...
(Date:3/3/2015)... 03, 2015 DePuy Pinnacle hip ... version of the artificial hip system caused recipients ... move forward in the federal multidistrict litigation underway ... According to the most recent Master Case List ... 7,350 Pinnacle hip replacement lawsuits are now pending ...
(Date:3/3/2015)... BC (PRWEB) March 03, 2015 The ... doubled since 1984 to about 15%. This increases to ... old. (Bushnik T, Cook JL, Yuzpe AA, et al. ... 2012; 27: 738-46). Dr. Jason Hitkari, a reproductive endocrinologist ... a doctor of TCM and clinical director and founder ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 ... is estimated to grow from $1,224.6 million ... 6.71% between 2014 and 2019. , Browse ... delivery network market for an analysis of ... of various tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html ...
Breaking Medicine News(10 mins):Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2Health News:TU-Automotive: Wawanesa Insurance to Discuss How UBI Can Produce Happy, Loyal Customers 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... HOPKINTON, Mass., Sept. 14 EMC Corporation (NYSE: ... infrastructure solutions, today announced that eClinicalWorks, a market leader ... provider customers, has consolidated and enhanced security of its ... As a result, eClinicalWorks has successfully managed rapid business ...
... , , ITASCA, Ill., Sept. 14 ... the JEWEL-OSCO grocery checkout. , , Starting today ... pharmacy will receive a special invitation to save a total of 20 ... avoid serious complications that can result from certain other illnesses or health conditions. ...
... , , , ... revealing that ten percent of Americans face dangerous drinking water, the Water ... their homes. , , On Sunday, the newspaper reported ... on "toxic waters." Among its findings: , , ...
... WILMINGTON, Del., Sept. 14 The airline and pharmaceutical industries ... can be dangerous if the risks are not properly calculated and ... experience of people who make and fly airplanes? , , ... a recent webinar on the topic - Captain Ben Berman, senior ...
... , , , ... today announced it has received the Frost & Sullivan 2009 ... of the Year Award . The award highlights PolyOne,s continuous innovations ... Walter Ripple, general manager, PolyOne,s GLS Thermoplastic Elastomers (TPEs), ...
... CHERRY HILL, N.J., Sept. 14 Nuvilex, Inc. (OTC Bulletin ... sponsored research studies indicate that Oraphyte(TM) can control nematode infestation ... coming months Nuvilex intends to initiate trials on golf course ... most optimal for turfgrass growth. These commercial studies will determine ...
Cached Medicine News:Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 3Health News:JEWEL-OSCO PHARMACY Offers Grocery Savings to Flu Shot Customers 2Health News:Home Filtering Systems Provide Best Drinking Water Protection 2Health News:Webinar Explores Drug Safety Lessons Pharma Can Learn from Airline Industry 2Health News:PolyOne Presented with Frost & Sullivan Medical Product Award 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 4
ELISA kit for Varicella-zoster IgM....
ELISA kit for Varicella-zoster IgG....
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
... Scientific, Inc. Mumps IgG ELISA test system ... Mumps IgG antibody in human serum. When ... of this test, together with other clinical ... immune status, and/or aid in the diagnosis ...
Medicine Products: